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David R. Holmes, JR, MD, Charanjit S. Rihal, MDI nterventional cardiology has focused on issuesof adjunctive therapy since the initial case ofpercutaneous transluminal coronary angioplasty
was performed by Andreas Grüntzig in September
1977. Several issues bear emphasis: 1) the need to
mitigate or eliminate the initial adverse effects of
mechanically disrupting the vascular architecture
of an atherosclerotic coronary artery; 2) prevention
of subsequent events such as early elastic recoil and
the later development of restenosis; 3) promoting
re-endothelialization after placing either a perma-
nent metallic or now a bioabsorbable structure for
scaffolding; 4) local drug delivery to enhance arterial
healing and prevent stent thrombosis (ST) with its
markedly increased associated risk of mortality and
morbidity; and ﬁnally 5) preventing other adverse
coronary events in areas remote from the initial
target lesion or vessel.
These adjunctive strategies have evolved over the
course of time: pioneers in the early stages of
interventional therapy development will recall such
diverse agents as dextran, colchicine, steroids, and a
variety of both anticoagulant and antiplatelet drugs.
Some of these strategies either did not work, were not
needed, or were associated with increased adverse
events.
A number of different principles of adjunctive
therapy have been substantiated and embedded in
guidelines, namely that dual antiplatelet agents are
necessary to improve the outcomes of now ubiqui-
tously used drug-eluting coronary stents. However,
important issues remain, not the least of which is*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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relevant to the contents of this paper to disclose.the duration of the antiplatelet therapy following
intervention as the interplay between risks and ben-
eﬁts tightens. This area and its interpretation have
been rendered more complex by the fact that anti-
platelet agents may also be used as a cornerstone for
secondary prevention of other lesions remote from
the stented arterial segment.
Despite an abundant literature that has grown up
around these issues, with multiple studies and now
multiple meta-analyses, it remains a moving target
as new knowledge accumulates (1–8). Currently, the
answer remains unclear to the point where the Amer-
ican College of Cardiology/American Heart Association
recommendations in the past have focused on longer
term >6 months of dual antiplatelet therapy (DAPT),
whereas the European Society of Cardiology recom-
mendations have typically focused on shorter-term
DAPT administration: #6 months in patients with
stable coronary artery disease. Interestingly, these
somewhat different guideline recommendations have
been reached by the authors of both guidelines who
have had access to the same literature. Considerations
in reaching these recommendations take into account
baseline patient acuity, extent of coronary disease,
predicted bleeding risk, and type of stents implanted.
However, even taking these into account, European
Society of Cardiology guidelines usually recommend a
somewhat shorter duration of DAPT, although both
sets of guidelines place increasing emphasis on the
importance of individualizing treatment based on
consideration of the risk–beneﬁt ratio (9,10).SEE PAGE 138In this issue of JACC: Cardiovascular Interventions,
the study by Hermiller et al. (11) focuses on one aspect
of the published pivotal multicentered randomized
trial DAPT, which included 25,682 patients after cor-
onary stenting (12,13). Details of that study are
important, including the fact that following stent
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149implantation, all patients were treated with DAPT for
1 year. If at the end of 1 year, no adverse events had
been identiﬁed, patients were then randomized
to either continued DAPT with a thienopyridine
(clopidogrel or prasugrel) plus aspirin, or placebo plus
aspirin for an additional 18months. Hermiller et al. (11)
focus on a post-hoc analysis of 4,703 patients initially
been treated with an everolimus-eluting stent (EES).
This is an important group for several reasons, but
predominantly because EES was the most common
drug-eluting stent used during the period of this study
(47.2%), and EES have been found to be associated
with particularly low rates of ST thought to be an
important mechanism of adverse coronary events
following drug-eluting stent implantation (14).
In this current analysis (11), continued thienopyr-
idine administration did not reduce the overall inci-
dence of clinically relevant adverse ischemic events
(death, myocardial infarction [MI], stroke 4.3% vs.
4.5%, p ¼ 0.42). On the risk side of the equation,
continued thienopyridine was associated with in-
creased moderate/severe bleeding (2.5% vs. 1.3%,
hazard ratio [HR]: 1.79, 95% conﬁdence interval [CI]:
1.15 to 2.80; p ¼ 0.01). Subgroup analyses of the
ﬁndings in this post-hoc analysis substantiated some
of the major conclusions reached in the initial
manuscript namely (10,11) continued thienopyridine
was associated with a further reduced rate of ST
(0.3% vs. 0.7%, HR: 0.38, 95% CI: 0.15 to 0.97;
p ¼ 0.04) and myocardial infarction (2.1% vs. 3.2%,
HR: 0.63, 95% CI: 0.44 to 0.91; p ¼ 0.01), but a higher
risk of death (2.2% vs. 1.1%, HR: 1.80, 95% CI: 1.11 to
2.92; p ¼ 0.02). This issue of increased mortality
with longer-term clopidogrel has been the subject of
concern and was dominantly related to malignancy.
Recently the Food and Drug Administration has
concluded that the preponderance of data does not
suggest that clopidogrel increases the risk of either
cancer or death related to cancer (15). It does, how-
ever, point to the risks of subgroup analyses and
zero-sum games.
Important considerations of large datasets such as
these relate to the number needed to treat for either
beneﬁt or harm and the tremendous statistical power
these large numbers deliver to detect small differ-
ences that may or may not be clinically important.
How to interpret these ﬁndings?
1. This is a post-hoc study with the inherent limita-
tions in such an approach.
2. Subgroup analyses is a zero-sum game because of
the issue of the potential to ﬁnd some results based
on chance alone.3. The authors, however, are to be commended for
this analysis in which they “suggest that the ther-
apeutic window for beneﬁt vs. risk of continued
thienopyridine therapy may be narrow.” Specif-
ically, the number needed to treat to beneﬁt 1
person for ST was 235 patients over 18 months,
whereas the number needed to treat to beneﬁt 1
person for MI was 98 over 18 months; by contrast,
the number need to treat for harm from moderate
or severe bleeding was 84.
These numbers are compelling as medicine moves
increasingly towards patient-centric care because
any treatment strategy requires evaluation of risks
and beneﬁts. These numbers also form part of the
background of the difference between guidelines and
clinical practice. As devices become increasingly
effective, risks from adjunctive therapy such as
bleeding may weigh more heavily in making indi-
vidualized therapeutic decisions. It must also be
remembered that not all subsequent cardiovascular
events are the result of stent-related problems. This
was highlighted in the PEGASUS (Prevention of
Cardiovascular Events [e.g., Death From Heart or
Vascular Disease, Heart Attack, or Stroke] in Patients
With Prior Heart Attack Using Ticagrelor Compared
to Placebo on a Background of Aspirin) trial TIMI-54
(Thrombolysis In Myocardial Infarction-54) (16),
which evaluated 21,162 patients 1 to 3 years post-MI
who were randomly assigned to either ticagrelor of
placebo. In this study, the primary composite
endpoint of cardiovascular death, MI, or stroke was
improved in patients treated with ticagrelor,
although bleeding was higher. Accordingly, it is
possible that longer-term DAPT, particularly in pa-
tients with extensive disease or an acute coronary
syndrome, may beneﬁt from more extensive, more
prolonged medical therapy irrespective of whether a
stent is present or not.
What then could be concluded from this analysis is
well stated by the authors: “ongoing analyses will
delineate the individual predictors of the risk and
beneﬁt of late continuation of (DAPT) treatment as
well as the absolute impact of late ischemic and
bleeding events and overall quantity and quality of
life.” Accordingly, for some patients, prolonged DAPT
may be apt, but this must be based on individualized
risk–beneﬁt assessment.
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